Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis.

Pillay P, Ford N, Shubber Z, Ferrand RA.

PLoS One. 2013 Jul 22;8(7):e68995. doi: 10.1371/journal.pone.0068995. Print 2013. Review.

2.

Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.

Mbuagbaw L, Mursleen S, Irlam JH, Spaulding AB, Rutherford GW, Siegfried N.

Cochrane Database Syst Rev. 2016 Dec 10;12:CD004246. doi: 10.1002/14651858.CD004246.pub4. Review.

3.

Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.

Mbuagbaw LC, Irlam JH, Spaulding A, Rutherford GW, Siegfried N.

Cochrane Database Syst Rev. 2010 Dec 8;(12):CD004246. doi: 10.1002/14651858.CD004246.pub3. Review. Update in: Cochrane Database Syst Rev. 2016 Dec 10;12 :CD004246.

PMID:
21154355
4.

Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.

Bannister WP, Ruiz L, Cozzi-Lepri A, Mocroft A, Kirk O, Staszewski S, Loveday C, Karlsson A, Monforte Ad, Clotet B, Lundgren JD; EuroSIDA study group.

AIDS. 2008 Jan 30;22(3):367-76. doi: 10.1097/QAD.0b013e3282f3cc35.

PMID:
18195563
5.

Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.

Cochrane Database Syst Rev. 2013 Jun 5;(6):CD008270. doi: 10.1002/14651858.CD008270.pub2. Review.

PMID:
23740608
6.

Comparative durability of nevirapine versus efavirenz in first-line regimens during the first year of initiating antiretroviral therapy among Swaziland HIV-infected adults.

Takuva S, Evans D, Zuma K, Okello V, Louwagie G.

Pan Afr Med J. 2013 May 3;15:5. doi: 10.11604/pamj.2013.15.5.1889. Print 2013.

7.

Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.

Lapphra K, Vanprapar N, Chearskul S, Phongsamart W, Chearskul P, Prasitsuebsai W, Chokephaibulkit K.

Int J Infect Dis. 2008 Nov;12(6):e33-8. doi: 10.1016/j.ijid.2007.10.008. Epub 2008 Jun 24.

8.

The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa.

Shearer K, Brennan AT, Maskew M, Long L, Berhanu R, Sanne I, Fox MP.

J Int AIDS Soc. 2014 Oct 22;17:19065. doi: 10.7448/IAS.17.1.19065. eCollection 2014.

9.

Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study.

Mwesigire DM, Wu AW, Martin F, Katamba A, Seeley J.

BMC Health Serv Res. 2015 Jul 28;15:292. doi: 10.1186/s12913-015-0959-0.

10.

Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.

Teeranaipong P, Sirivichayakul S, Mekprasan S, Ohata PJ, Avihingsanon A, Ruxrungtham K, Putcharoen O.

PLoS One. 2016 Apr 27;11(4):e0154221. doi: 10.1371/journal.pone.0154221. eCollection 2016.

11.

Effectiveness of efavirenz-based regimens in young HIV-infected children treated for tuberculosis: a treatment option for resource-limited settings.

van Dijk JH, Sutcliffe CG, Hamangaba F, Bositis C, Watson DC, Moss WJ.

PLoS One. 2013;8(1):e55111. doi: 10.1371/journal.pone.0055111. Epub 2013 Jan 25.

12.
13.

Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral therapy in a South African multicentre cohort.

Bock P, Fatti G, Grimwood A.

Int Health. 2013 Jun;5(2):132-8. doi: 10.1093/inthealth/iht002.

PMID:
24030113
14.

Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults.

Nachega JB, Hislop M, Dowdy DW, Gallant JE, Chaisson RE, Regensberg L, Maartens G.

AIDS. 2008 Oct 18;22(16):2117-25. doi: 10.1097/QAD.0b013e328310407e.

15.

Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study.

Keiser P, Nassar N, White C, Koen G, Moreno S.

HIV Clin Trials. 2002 Jul-Aug;3(4):296-303.

PMID:
12187503
16.

Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults.

Siegfried NL, Van Deventer PJ, Mahomed FA, Rutherford GW.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD004535. Review.

PMID:
16625606
17.

Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection.

Manosuthi W, Sungkanuparph S, Vibhagool A, Rattanasiri S, Thakkinstian A.

HIV Med. 2004 Mar;5(2):105-9.

18.

Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.

van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, Wood R, Bloch M, Katlama C, Kastelein JJ, Schechter M, Murphy RL, Horban A, Hall DB, Lange JM, Reiss P.

PLoS Med. 2004 Oct;1(1):e19. Epub 2004 Oct 19. Erratum in: PLoS Med. 2004 Dec;1(3):e73.

19.

Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons.

van den Berg-Wolf M, Hullsiek KH, Peng G, Kozal MJ, Novak RM, Chen L, Crane LR, Macarthur RD; CPCRA 058 Study Team, the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA), and The International Network for Strategic Initiative in Global HIV Trials (INSIGHT).

HIV Clin Trials. 2008 Sep-Oct;9(5):324-36. doi: 10.1310/hct0905-324.

PMID:
18977721
20.

Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.

Manosuthi W, Mankatitham W, Lueangniyomkul A, Chimsuntorn S, Sungkanuparph S.

HIV Med. 2008 May;9(5):294-9. doi: 10.1111/j.1468-1293.2008.00563.x.

Supplemental Content

Support Center